An interventional study of ENDURE in Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma and Oropharynx Cancer, sponsored by Medical University of South Carolina. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Head and Neck Neoplasms by Medical University of South Carolina — 6 open to participants now, 6 under way, none of them phase 3. Head and Neck Neoplasms · Medical University of South Carolina.
Among the 17 studies in Head and Neck Neoplasms by Medical University of South Carolina, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 with no phase, and was the 14th registered.
2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.
Browse Head and Neck Neoplasms studies →6 of the 17 studies in Head and Neck Neoplasms by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 532 is above the median of 46 across 2,036 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 30 across the 15 interventional studies, 65 across the 2 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
1 of the studies in Head and Neck Neoplasms by Medical University of South Carolina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05442957Medical University of South CarolinaBuilding a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Head and Neck Neoplasms by Medical University of South Carolina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are:
In this hybrid type 1 effectiveness-implementation study, the investigators will conduct a stepped-wedge cluster randomized trial with cancer centers (n=4; 484 patients) randomized to sequentially deliver treatment as usual (TAU) then ENDURE to patients with head and neck cancer undergoing surgery and postoperative radiation therapy (PORT). The trial will assess the effect of ENDURE vs TAU on improving initiation of timely PORT (primary objective) and the underlying mechanisms of ENDURE (secondary objective). The investigators will concurrently conduct a mixed-methods study with quantitative measures of implementation outcomes and qualitative data about implementation determinants from semi-structured interviews with key stakeholders and site visits (exploratory objective).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ENDURE is a theoretically-informed, navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT.
Behavioral: ENDURE
Treatment as usual at each site consists of standard of care clinical practices
ENDURE provides patient education through the ENDURE Patient Resource Guide and social support by linking patients to community resources (patient-level), standardizes discussions about expectations for PORT and clinical documentation to enhance communication and care coordination within and across interprofessional cancer teams (team-level), and implements referral tracking across fragmented health systems (organization-level). To facilitate care coordination, ENDURE modifies existing standard of care patient navigation (an evidence-based intervention that addresses barriers to timely cancer care) by adding PORT-focused navigation at three key care transitions: into the cancer care system; from inpatient to outpatient after surgery; and from the surgical team to the radiation oncology team.
Initiation of Timely PORT
The initiation of PORT \> 6 weeks (42 days) following definitive surgery for HNSCC.
Time frame: 3 months
Time-to-PORT
The number of days from the date of definitive surgery for HNSCC to the date of initiation of PORT.
Time frame: 4 months
Pre-Surgical consultation with radiation oncology
Consultation with a treating radiation oncologist prior to definitive surgery for HNSCC.
Time frame: 1 month
Pre-radiation therapy dental extractions
The removal of indicated carious/non-restorable teeth prior to or during the surgery for HNSCC.
Time frame: 1 month
Time to postoperative scheduling with radiation oncology
The time from definitive surgery to the placement of the postoperative referral (or follow-up appointment) with the treating radiation oncologist.
Time frame: 3 months
Time to postoperative appointment with radiation oncology
Time from definitive surgery to the attendance at an appointment with the treating radiation oncologist.
Time frame: 3 months
Plan to share: Yes — Below are the key elements of the data sharing plan as outlined in the NIH Policy for Data Management and Sharing: Research materials will include: (1) self-report measures from patients; (2) clinical data from the electronic medical record; (3) audio recordings and transcriptions of interviews from stakeholders; and (4) field notes from direct observations of the delivery of ENDURE at each site. Data will be raw or minimally processed. The investigators plan to use REDCap for data capture and management of the clinical and self-report measure data and NVivo for management of the qualitative data. REDCap data dictionaries can be distributed for reuse. The final data dictionaries have not been developed. Scientific data and metadata will be generated, preserved, and shared using NIH common data elements. Scientific data and metadata arising from the project will be uploaded to openICPSR, a self-publishing repository for social, behavioral, and health sciences research data.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data will be shared no later than the time of a publication of findings of the trial's primary endpoint in a peer-reviewed journal.
Access criteria: All data sharing will comply with privacy and confidentiality protections such as the NIH Certificate of Confidentiality and applicable laws, regulations, and policies governing data derived from human participants.
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Mar 2028, 53 months after the start.
Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 53 months is above that.
Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →